Analysed TSCAN THERAPEUTICS INC (TCRX:NASDAQ) News Sources
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
06-05-2026
yahoo.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
03-06-2026
yahoo.com
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
22-06-2026
yahoo.com
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
24-06-2026
yahoo.com
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
29-07-2026
yahoo.com
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
12-08-2026
yahoo.com
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
02-09-2026
yahoo.com
What is the current price of TSCAN THERAPEUTICS INC (TCRX:NASDAQ)?
The current price of TSCAN THERAPEUTICS INC (TCRX:NASDAQ) is $0.3281.
TSCAN THERAPEUTICS INC (TCRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TSCAN THERAPEUTICS INC (TCRX:NASDAQ) since the previous trading day is $0.0077.
TSCAN THERAPEUTICS INC (TCRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TSCAN THERAPEUTICS INC (TCRX:NASDAQ) since the previous trading day is 2.4032%.
What is the most recent average sentiment score for TSCAN THERAPEUTICS INC (TCRX:NASDAQ)?
The most recent average sentiment score for TSCAN THERAPEUTICS INC (TCRX:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for TSCAN THERAPEUTICS INC (TCRX:NASDAQ)?
The most recent sentiment for TSCAN THERAPEUTICS INC (TCRX:NASDAQ) is .
SEC-8K** Filing Available For TSCAN THERAPEUTICS INC (TCRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.